ImmunoPrecise Antibodies’ LENSai Platform Achieves Breakthrough in Epitope Mapping Accuracy

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ImmunoPrecise Antibodies announced significant validation for its proprietary epitope mapping platform, called LENSai. This platform is powered by IPA’s patented HYFT technology and has shown its ability to accurately predict antibody binding sites even on therapeutic targets it has never encountered before in its training data.

A new benchmark study tested LENSai on 30 antibody-protein pairs, 17 of which were entirely new to the platform, so LENSai had no prior exposure to these specific antibodies, targets, or complexes. Despite this, LENSai achieved prediction scores, measured by AUC (Area Under the Curve), that were nearly identical to those obtained from its original training data.

A scientist analyzing antibodies in a lab.

The consistent high performance on unseen complexes confirms LENSai’s generalizability and its ability to reliably analyze and predict antibody binding for diverse biological structures, achieving near-crystallography precision. Traditional epitope mapping methods can take months and require extensive wet-lab work and expensive materials. In contrast, LENSai delivers results in hours using only digital sequences. ImmunoPrecise is already integrating LENSai into collaborations with major pharmaceutical and biotech companies, as well as scaling access through secure APIs and custom partnerships.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) is a techbio company that uses multi-omics modeling and complex AI through a series of proprietary and patented technologies, and supports the discovery and development of therapeutic antibodies.

While we acknowledge the potential of IPA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.